Barclays has initiated coverage on Henry Schein Inc (HSIC) with an Overweight rating, marking the firm's first assessment of the company. This rating reflects Barclays' analysis of Henry Schein's business dynamics and growth potential within the health care sector.
Headquartered in Melville, New York, Henry Schein provides a wide range of health care products and services to medical, dental, and veterinary practitioners. The company operates through several segments, including Global Distribution and Value-Added Services, Global Specialty Services, and Global Technology. As of December 9, 2025, Henry Schein's stock is priced at $77.05, and the company boasts a market capitalization of $8.8 billion and a P/E ratio of 22.40.
Upcoming earnings reports are anticipated on May 4, 2026, and August 3, 2026, with estimated earnings per share of $1.29 and $1.24, respectively. The recent performance has shown mixed results, with Q3 2025 reporting an EPS of $1.38, surpassing estimates by 5.8%.
Analyst ratings serve as professional opinions based on comprehensive research and financial models. While they provide valuable insights, they should be considered alongside other factors, including company fundamentals and market conditions. Over time, analyst ratings may evolve as new information emerges, highlighting the importance of a well-rounded approach to investment decisions.